Correlation between epidermal growth factor receptor mutations and the expression of estrogen receptor-α in advanced non-small cell lung cancer
Correlation between epidermal growth factor receptor mutations and the expression of estrogen receptor-α in advanced non-small cell lung cancer
复制标题
DOI：
10.3892/ol.2017.5711
复制
发表时间：
2017-04-01
期刊：
影响因子：
2.9
通讯作者：
Wang, Bao-Long
中科院分区：
文献类型：
--
作者：
Deng, Fang;Li, Ming;Wang, Bao-Long
表皮生长因子受体(EGFR)突变在非小细胞肺癌(NSCLC)和东亚起源的女性患者中更为常见。因此，本研究调查了晚期NSCLC中EGFR突变的存在，并评估了其与临床病理因素的相关性，包括雌激素受体-β(ER-β)的表达和患者的预后。本研究对83例IIIB-IV期非小细胞肺癌患者进行了回顾性分析。免疫组织化学方法检测ER-β和P53蛋白的表达。用扩增难治性突变系统检测EGFR突变。ER-β和P53的阳性表达分别为37例(45.6%)和48例(57.8%)。36例(45.4%)发现EGFR突变。EGFR突变在ERβ阴性肿瘤中的发生率(26/46；56.5%)高于ERβ阳性肿瘤(10/37；27%)。ER-β表达与表皮生长因子受体突变显著相关，优势比(OR)为0.241(P=0.029)。而p53的表达与表皮生长因子受体基因突变之间无明显相关性(OR=1.792；P=0.340)。此外，ER-β的表达和淋巴结转移与预后不良有关，而EGFR基因突变与预后良好的无进展生存率显著相关。然而，P53的表达与预后无关。总之，ER-β的表达与EGFR突变的存在显著相关。ER-β表达和EGFR突变是影响晚期非小细胞肺癌患者生存率的预后因素。
Epidermal growth factor receptor (EGFR) mutations are more common in non-small cell lung cancer (NSCLC) and in female patients of East Asian origin. Therefore, the present study investigated the presence of EGFR mutations in advanced NSCLC, and assessed its correlation with clinicopathologic factors, including the expression of estrogen receptor-beta (ER-beta) and patient prognosis. The present study performed a retrospective analysis of 83 patients with stage IIIB-IV NSCLC. The expression of ER-beta and p53 were examined using immunohistochemical methods. EGFR mutations were evaluated using the amplification refractory mutation system. The expression of ER-beta and p53 were detected in 37 (45.6%) and 48 (57.8%) of the patient tumors, respectively. EGFR mutations were identified in 36 (45.4%) cases. EGFR mutations were more frequently observed in ER-beta-negative tumors (26/46; 56.5%), compared with ER-beta-positive tumors (10/37; 27%). The expression of ER-beta was significantly associated with EGFR mutations with an odds ratio (OR) of 0.241 (P=0.029). However, no significant correlation was observed between the expression of p53 and mutations in EGFR (OR=1.792; P=0.340). In addition, the expression of ER-beta and lymph node metastasis were associated with poor prognosis, whereas EGFR mutations were significantly associated with favorable prognosis in terms of progression-free survival rates. However, there was no prognostic significance associated with the expression of p53. In conclusion, the expression of ER-beta was significantly correlated with the presence of EGFR mutations. The expression of ER-beta and mutations of EGFR were found to be prognostic factors for survival rates in patients with advanced NSCLC.